Intraarterial application of Octreotide

PreclinicalPeptide

Intraarterial application of Octreotide is one of 5 small molecule programs targeting Pancreatic. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PancreaticCompleted

PancreaticPreclinical

Completed

Competition

Competitive Landscape

5 competitors in Pancreatic

#DrugCompanyPhaseTrials

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1

1 2

Pancreatic Parenchymal of N-Butyl-2-Cyanoacrylate

MMinia University

Phase 2

1 3

Synthetic Human Secretin

MMayo Clinic

Preclinical

2 4

Proton Pump Inhibitors

SSamsung Medical Center

Preclinical

1 5

Intraarterial application of Octreotide

SSt. Josef Hospital Bochum

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pancreatic1 trial

Effects of Intraarterial Octreotide on Pancreatic Texture

Completed·SSt. Josef Hospital Bochum·N/A·NCT01400100·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intraarterial application of Octreotide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intraarterial application of Octreotide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intraarterial application of Octreotide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St. Josef Hospital Bochum company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Preclinical[1]
Company: SSt. Josef Hospital Bochum

Intraarterial application of Octreotide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pancreatic1 trial

References

Drug Info

Quick Facts

Related News